Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245881 | 0.99 | TDP1 (0.51) | TDP1MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL4249017 | 0.97 | TDP1 (0.48) | TDP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4249944 | 0.92 | TDP1 (0.56) | TDP1MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL4245882 | 0.91 | NPC1 (0.42) | TDP1POLBSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL4242119 | 0.90 | TDP1 (0.67) | TDP1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL4243996 | 0.90 | TDP1 (0.53) | TDP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4245834 | 0.90 | NPC1 (0.43) | TDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL4248962 | 0.89 | TDP1 (0.65) | TDP1KMT2APOLBALDH1A1TP53 | |
| SCHEMBL4244678 | 0.88 | NPC1 (0.40) | TDP1L3MBTL1 | |
| SCHEMBL4247544 | 0.88 | TDP1 (0.49) | TDP1MEN1KMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902400-B2 | N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20090131531-A1 | Amide Compounds and their Use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131531-A1 | Amide Compounds and their Use | NAT1, ACAT2, NAAA | TDP1 3052/4885MEN1 3713/4885KMT2A 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.